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Abstract. The aim of the present study was to report on a
complete synthetic approach, namely benzylation‑hydrolysis‑acylation‑hyd rogenation, to the synthesis of
regioselectively acylated quercetin analogues using low‑cost
rutin as a starting material. Three quercetin analogues, quercetin‑3‑O‑propionate (Q‑pr), quercetin‑3‑O‑butyrate (Q‑bu)
and quercetin‑3‑O‑valerate (Q‑va), containing 3‑, 4‑ and
5‑carbon aliphatic acyl chains, respectively, were synthesized
and characterized with 1H nuclear magnetic resonance (NMR),
13
C NMR and mass spectrometry. Compared with quercetin,
all three analogues exhibited improved lipophilicity. The
lipophilicity of the analogue increased with increasing acyl
chain length. Q‑va exhibited the highest lipophilicity among
the three analogues, but a lower water solubility compared
with quercetin. By contrast, Q‑pr and Q‑bu exhibited 8.2‑ and
4.7‑fold higher water solubility compared with quercetin,
respectively. The in vitro and in vivo studies demonstrated
that Q‑pr and Q‑bu were more effective whereas Q‑va was
less effective in inhibiting platelet aggregation compared with
quercetin. These results indicated that the water solubility and
the lipophilicity of the analogues must be improved in order to
achieve higher antiplatelet activity, and an optimal acyl chain
length is crucial for the synthesized quercetin analogues to be
more effective.

Correspondence to: Dr Yu Duan, School of Pharmacy,
Weifang Medical College, 7166 West Baotong Road, Weifang,
Shandong 261053, P.R. China
E‑mail: duanyu@wfmc.edu.cn

Dr Hu Yang, Department of Chemical and Life Science Engineering,
Virginia Commonwealth University, 401 West Main Street,
Richmond, VA 23119, USA
E‑mail: hyang2@vcu.edu
*

Contributed equally

Key words: quercetin, regioselective acylation, water solubility,
oil‑water partition coefficient, antiplatelet aggregation

Introduction
Quercetin is the most abundant dietary flavonoid (1). It was
previously demonstrated that quercetin exerts an antiplatelet
effect that may be utilized to prevent and alleviate cardiovascular diseases (2‑8). However, quercetin exhibits low
hydrophilicity and low water solubility. In particular, the low
water solubility is associated with the limited bioavailability
of quercetin, and remains as a major obstacle to its therapeutic
applications (9,10). The strong intermolecular packing of
planar phenyl and hereto rings among quercetin molecules
is presumably attributed to the low solubility of quercetin in
water. Acylation of the hydroxyl groups of quercetin by an
acyl donor containing a short aliphatic chain is a feasible way
for destroying this intermolecular packing, hence improving
the solvation of quercetin. However, non‑selective acylation
of hydroxyl groups may lead to loss of the biological activities of quercetin. The two adjacent hydroxyl groups at C3 and
C4 in ring B, and the double bond between C2‑C3 and the
carbonyl group at C4 in ring C, are the most critical elements
for quercetin to be biologically active (11,12). Therefore, to
improve quercetin water solubility without compromising
its biological activities, these functional groups must be kept
intact.
Regioselective acylation of the hydroxyl group at C3 offers
a reasonable solution (13,14). Chemo‑enzymatic synthesis
of regioselectively acylated quercetin has been previously
investigated (13‑17). However, synthesis methods without
using enzymes are desirable, as they may reduce the reaction
time and eliminate the need for costly enzymes. Only few
studies using enzyme‑free synthesis methods for the synthesis
of quercetin analogues have been reported to date (18). A
major challenge is that quercetin's hydroxyl groups may be
randomly acylated, yielding a mixture of products. The aim
of the present study was to develop a complete synthetic
method (benzylation‑hydrolysis‑acylation‑hydrogenation) for
the synthesis of quercetin analogues using low‑cost rutin as a
starting material. With this method, regioselective acylation
of C3 becomes possible as the hydroxyl of C3 is naturally
protected with glycoside via a glycosidic bond. Three quercetin
analogues were synthesized, quercetin‑3‑O‑propionate (Q‑pr),
quercetin‑3‑O‑butyrate (Q‑bu) and quercetin‑3‑O‑valerate
(Q‑va), with high yields (Fig. 1), and their water solubility,
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lipophilicity and antiplatelet activity were examined against
quercetin.
Materials and methods
Chemicals. Rutin (≥98%) was obtained from Nanjing TCM
Institute of Chinese Materia Medica (Nanjing, China) and
kept at 110˚C under 1.3 kPa for 12 h to remove bound water.
Propionyl chloride, butyryl chloride and valeroyl chloride
(analytical grade) were purchased from Aladdin Industrial
Corporation (Shanghai, China). Benzyl bromide was obtained
from Sinopharm Chemical Reagent (Shanghai, China) and
distilled prior to use. N,N‑dimethylformamide (DMF), triethylamine (TEA), and dichloromethane (DCM) were purchased
form Tianjin Kemiou Chemical Reagent (Tianjin, China) and
dehydrated prior to use. Adenosine diphosphate (ADP), arachidonic acid (AA) and platelet‑activating factor (PAF) were
purchased from Sigma‑Aldrich (Merck KGaA, Darmstadt,
Germany). Palladium on carbon (Pd/C) (10%) was obtained
from Sinopharm Chemical Reagent.
Animals. Male New Zealand rabbits (license no. 0017075)
and male Wistar rats (250‑300 g; license no. 0010061) were
obtained from the Experimental Animal Center of Shandong
Lukang Pharmaceutical (Jinan, China). The experimental
procedures were approved by the Animal Experimentation
Ethics Committee of Weifang Medical College and conducted
in accordance with the guidelines of the National Health and
Medical Research Council of China for the care and use of
animals.
Synthesis of acylated quercetin analogues. The synthesis
followed a complete chemical synthetic procedure, namely
benzylation‑hydrolysis‑acylation‑hydrogenation, using rutin
as the starting material.
Step 1. Rutin (24.42 g, 40 mmol) and K 2CO3 (18.35 g,
133 mmol) were sequentially added to 160 ml of DMF
under nitrogen and stirred for 1 h at room temperature (19).
Subsequently, benzyl bromide (16 ml, 133 mmol) was added
dropwise into the reaction mixture. The reaction mixture was
stirred at 40˚C for 3 h under nitrogen, and then adjusted to pH
6.0 with 10% (v/v) acetic acid in ice bath. Deionized water
(300 ml) was then added to this mixture and the suspension
was filtered.
Step 2. The filtered residue was dissolved in 600 ml of
95% (v/v) ethanol at 70˚C. Hydrochloric acid [90 ml, 36%
(w/w)] was added to the solution and the hydrolysis continued
at 70˚C for 2 h. The suspension was cooled down to room
temperature and then filtered to yield hydrolyzate. The
hydrolyzate was washed with ice water until its pH became
neutral.
Step 3. The hydrolyzate was dissolved in 250 ml of DCM
followed by addition of chloride (propionyl chloride, butyryl
chloride or valeroyl chloride) (44 mmol) and TEA (44 mmol).
The mixture was stirred at room temperature until thin‑layer
chromatography (TLC) analysis showed the completeness of
the reaction. The reaction mixture was then extracted with
1 mol/l hydrochloric acid, and the organic layer was washed
with a saturated aqueous solution of NaHCO3 and deionized water. The pooled extracts were dried over Na2SO4 and

Figure 1. Chemical structures of quercetin and the synthesized quercetin
analogues. Q‑pr, quercetin‑3‑O‑propionate; Q‑bu, quercetin‑3‑O‑butyrate;
Q‑va, quercetin‑3‑O‑valerate.

then taken to dryness under vacuum to retrieve the acylated
compound.
Step 4. The acylated compound was dissolved in 5,000 ml of
ethanol/dioxane (1:1, v/v). Pd/C (2 g) was added to the solution.
The reaction mixture was stirred at room temperature under
hydrogen at atmospheric pressure for 2 h. Pd/C was filtered off,
and the filtrate was evaporated in vacuum to retrieve the crude
product of acylated quercetin analogues.
Purification of acylated quercetin analogues. Acylated
derivatives were purified by using semi‑preparative
high‑performance liquid chromatography (HPLC). An
Agilent 1200 infinity preparative chromatography system
performed chromatographic separation; this system was
equipped with an Agilent Prep LC controller, an ultraviolet (UV) detector (VWD‑G1314B), a preparative column
(ZORBAX‑SB C18, 250x9.4 mm, 5 µm), an injector (3725i)
and an auto‑fraction collector (G1364C) (all from Agilent
Technologies, Inc., Santa Clara, USA). Q‑pr and Q‑bu were
purified using the linear elutions of acetonitrile/water (40:60,
v/v and 30:70, v/v, respectively). Q‑va was purified using a
linear gradient of acetonitrile and water for 0 min (30:70, v/v),
7 min (40:60, v/v), 15 min (50:50, v/v), and 25 min (30:70, v/v).
The flow rate was 5 ml/min, and the elution was performed at
room temperature at 254 nm with the UV detector.
TLC. The acylation process was monitored using TLC on
silica gel 60‑GF254 (Merck KGaA), with a solvent mixture of
ethyl acetate, methanol and acetic acid (at a ratio of 6:4:0.1,
v/v/v). The plate was observed and detected under UV light
(254 nm).
Nuclear magnetic resonance (NMR) spectroscopy and mass
spectrometry (MS). Quercetin and three acylated derivatives,
Q‑pr, Q‑bu and Q‑va, were characterized with 1H NMR
(500 MHz) and 13C NMR (100 MHz) in DMSO‑d 6 using a
Bruker AV500 NMR spectrometer (Bruker Corporation,
Billerica, MA, USA) with tetramethylsilane as an internal
reference, and with MS without breaking into fragment
ions using an Agilent 6410 liquid chromatography‑mass
spectrometer (Agilent Technologies, Inc.) with electrospray
ionization.
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Water solubility measurements. The water solubility of
quercetin and the three acylated derivatives was determined
according to the method described by Bonina et al (20). An
excess amount of the compound was weighed into a glass
tube containing 2 ml of water, and the tube was sealed with a
Teflon‑lined cap. The mixture was stirred by a magnetic stirrer
for 24 h at room temperature and was then filtered using a
Millex HV13 filter unit (0.22 µm; Merck KGaA). The drug
concentration in the saturated solution at 254 nm was determined using a Shimadzu chromatography system (LC‑20AT),
equipped with a UV detector (SPD‑M10Avp) and a column
(Shim‑pack VP‑ODS C18, 250x4.60 mm, 5 µm) (all from
Shimadzu, Kyoto, Japan). The mobile phase was water/methanol (70:30, v/v) at a flow rate of 1 ml/min.
Lipophilicity measurements. Lipophilicity may be estimated
using reverse‑phase chromatographic retention time due to the
good association between the logarithm of the n‑octanol/water
partition coefficient (log P) and the logarithm of the capacity
factor eluting with 100% water (log kw) determined using
octadecyl silica columns. The value of log kw was obtained
according to the method described by Braumann (21). Each
compound was dissolved in methanol to a final concentration
of 10 µg/ml. The sample (n=3) was filtered prior to injection
using a filter (Millex HV13, 0.22 µm; Merck KGaA) and the
aliquot (20 µl) was injected into the HPLC. The value of logarithm of the capacity factor (log k') was calculated using the
following equation:

where t r is the retention time of the flavonoid peak and t 0
denotes the retention time of the non‑retained solvent peak.
The HPLC condition was maintained the same as in the water
solubility test. Only the volume fraction of methanol in mobile
phase was changed for each measurement. A series of values
of retention times and log k' were obtained. At a plot of log
k' vs. the volume fraction of methanol in mobile phase, φ,
extrapolated the data to 100% water to obtain the intersection
point with the y axis, that is log kw value. A formula (21), which
exhibited an excellent correlation between log kw and log P for
the compound containing conjugated aromatic, was selected to
calculated the value of log P:
log k w = 0.988 x log P + 0.020
The lipophilicity of quercetin and the three acylated
derivatives was also calculated using the ACD/ChemSketch
(Advanced Chemistry Development Inc., Toronto, Canada)
and the Property Explorer Applet (www. openmolecules. org).
The association between log k' and φ, the values of log kw
and log P of quercetin and the three acylated derivatives are
presented in Table I.
In vitro antiplatelet activity test. Fresh whole blood was
collected from healthy male New Zealand rabbits with 3.8%
(w/v) sodium citrate at a volume ratio of 9:1. Platelet‑rich
plasma (PRP) was obtained by centrifugation at 328.7 x g for
8 min at room temperature with no brake. PRP (300 µl) was
incubated for 3 min at 37˚C in the presence of various final
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concentrations (0‑350 µM) of quercetin or acylated analogue
(n=8‑10), predissolved in DMSO. The final concentration of
DMSO was <1.0% (v/v) to eliminate false positive results.
Subsequently, platelet aggregation was stimulated by ADP
(7 µM), AA (350 µM), or PAF (7.2 nM). The aggregation
was monitored for 5 min using a platelet aggregometer
(LBY‑NJ4A, Precill, Beijing, China) with constant stirring
at 241.5 x g, and the aggregation rates were recorded to
determine the percentage of aggregation.
In vivo antiplatelet activity test. Administration of
investigational agents and sample preparation for platelet
aggregation were performed according to the method described
by Mosawy et al (22). In brief, the rats (8‑10 per group) were
treated with 0.03 mmol/kg quercetin, Q‑pr, Q‑bu, Q‑va, or
control consisting of 0.5% DMSO with 2.2 mM polyethylene
glycol (PEG) in saline. DMSO and PEG were used to improve
the solubility of the investigational agents in the blood. The
investigational agents were administered via a single intravenous (IV) bolus via the tail vein. Experimental procedures and
blood sample collection were performed 30 min after the IV
bolus treatment. In each rat, 5 ml of fresh whole blood was
collected into tubes containing 600 µl of 3.8% (w/v) sodium
citrate via cardiac puncture. PRP was obtained by centrifugation at 377.3 x g for 8 min at room temperature with no brake.
PRP was incubated for 3 min at 37˚C, and platelet aggregation
was then stimulated by 7 µM ADP, 350 µM AA, or 7.2 nM
PAF (final concentration). The aggregation was monitored
for 5 min by using an aggregometer (LBY‑NJ4A, Precill) at a
constant stirring of 241.5 x g, and the aggregation rates were
recorded to determine the percent of aggregation. The value
of the aggregation inhibitory rate (AIR) was calculated as
follows:

where A is the platelet aggregation rate of the sample and B is
the platelet aggregation rate of the no compound treated group
(control).
Statistical analysis. All values a re expressed as
mean ± standard error of the mean. Comparisons between test
samples and blank were performed using SPSS 9.0 software
for Windows (SPSS Inc., Chicago, IL, USA) with Dunnett's
test for post hoc comparisons, and P≤0.01 was considered to
indicate statistically significant differences.
Results and Discussion
The synthesis of the three quercetin analogues involves
four steps (Fig. 2). The hydroxyl group at C5 is considered
non‑reactive, as it forms an intramolecular hydrogen bond
with the carbonyl at C4 (22). Therefore, this hydroxyl group
remained intact throughout the reactions. In step 1, anhydrous
K2CO3 was added to facilitate the formation of oxygen anions
for hydroxyl groups at C3, C4 and C7 of rutin. Subsequently,
benzyl bromide was added to benzylate the forming oxygen
anions. A protic solvent, DMF, was used to avoid the production of C‑alkylated derivatives. The hydroxyl group at C3
was recovered after hydrolysis of the glycoside (step 2), and
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Table I. Association between log k' and φ, and values of log kw, log P and water solubility of quercetin, Q‑pr, Q‑bu and Q‑va.
			 log Pb
‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Compound
log k'‑φ (Ra)
log kw
A
B
C
Quercetin
Q‑pr
Q‑bu
Q‑va

log k'=1.67–2.16φ (R=‑0.98221)
log k'=3.04–4.21φ (R=‑0.9837)
log k'=3.47–4.41φ (R=‑0.9943)
log k'=3.72–4.77φ (R=‑0.9995)

1.67
3.04
3.47
3.72

1.67
3.06
3.48
3.75

2.07
2.77
3.30
3.83

1.49
2.43
2.88
3.34

Water solubility (µg/ml)
1.98
16.27
9.36
1.07

Linear correlation coefficient. blog P was calculated as follows: A, according to the formula log kw=0.988–log POCT+ 0.020; B, using the
ACD/ChemSketch; C, using the Property Explorer Applet (www.openmolecules.org). Q‑pr, quercetin‑3‑O‑propionate; Q‑bu, quercetin‑3‑O‑butyrate; Q‑va, quercetin‑3‑O‑valerate.
a

became the only reactive group for subsequent acylation in
step 3. In the final step, the benzyl groups at C3, C4 and C7
were removed by hydrogenation. The resulting acylated quercetin derivatives were purified using semi‑preparative HPLC.
All these derivatives were yellow powders.
The 1H NMR, 13C NMR and MS spectra collectively
confirmed the structures of regioselectively acylated quercetin
analogues.
Q‑pr. 1H NMR chemical shifts: δ (ppm) 12.23 (1H, s, 5‑OH),
10.67 (1H, br, s, 7‑OH), 9.72 (3H, br s, 3, 3', 4'‑OH), 7.33 (1H, d,
H‑2'), 7.27 (1H, d, H‑6'), 6.92 (1H, d, H‑5'), 6.48 (1H, d, H‑8),
6.25 (1H, d, H‑6), 2.68 (2H, t, CH2), 1.15 (3H, t, CH3). 13C NMR
chemical shifts: δ (ppm) 175.39 (C‑4), 171.78 (C=O), 165.18
(C‑7), 161.54 (C‑9), 157.08 (C‑5), 156.36 (C‑2), 149.78 (C‑4'),
145.95 (C‑3'), 130.06 (C‑3), 120.98 (C‑1'), 120.08 (C‑6'), 116.45
(C‑5'), 115.46 (C‑2'), 103.89 (C‑10), 99.55 (C‑6), 94.56 (C‑8),
27.08 (CH2), 9.32 (CH3). MS (m/z) for Q‑pr: 381.1 [M+Na]+.
Q‑bu. 1H NMR chemical shifts: δ (ppm) 12.20 (1H, s,
5‑OH), 7.32 (1H, d, H‑2'), 7.26 (1H, d, H‑6'), 6.91 (1H, d, H‑5'),
6.47 (1H, d, H‑8), 6.25 (1H, d, H‑6), 2.63 (2H, t, CH2), 1.66 (2H,
m, CH2), 0.96 (3H, t, CH3). 13C NMR chemical shifts: δ (ppm)
174.95 (C‑4), 170.48 (C=O), 164.72 (C‑7), 161.08 (C‑9), 156.63
(C‑5), 156.01 (C‑2), 149.31 (C‑4'), 145.45 (C‑3'), 129.56 (C‑3),
120.54 (C‑1'), 119.60 (C‑6'), 115.95 (C‑5'), 115.01 (C‑2'), 103.55
(C‑10), 99.11 (C‑6), 94.12 (C‑8), 28.85 (CH 2), 17.88 (CH 2),
13.33 (CH3). MS (m/z): 395.1 [M+Na]+.
Q‑va. 1H NMR chemical shifts: δ (ppm) 12.23 (1H, s,
5‑OH), 7.32 (1H, d, H‑2'), 7.27 (1H, d, H‑6'), 6.92 (1H, d, H‑5'),
6.48 (1H, d, H‑8), 6.25 (1H, d, H‑6), 2.65 (2H, t, CH2), 1.62
(2H, m, CH2), 1.36 (2H, m, CH2), 0.90 (3H, m, CH3). 13C NMR
chemical shifts: δ (ppm) 175.40 (C‑4), 171.01 (C=O), 165.22
(C‑7), 161.55 (C‑9), 157.09 (C‑5), 156.48 (C‑2), 149.77 (C‑4'),
145.97 (C‑3'), 130.04 (C‑3), 122.97 (C‑1'), 120.07 (C‑6'), 116.38
(C‑5'), 115.49 (C‑2'), 103.89 (C‑10), 99.56 (C‑6), 94.56 (C‑8),
33.30 (CH2), 26.85 (CH2), 21.93 (CH2), 14.04 (CH3). MS (m/z):
409.1 [M+Na]+.
In the 13C NMR spectrum of quercetin, the chemical shift
of C3 appears at 136.18 ppm. However, the chemical shift of
C3 in the synthesized analogues moved upfield (130.06 ppm
for Q‑pr, 129.56 ppm for Q‑bu, and130.04 ppm for Q‑va).
Furthermore, the chemical shifts attributed to the ester
carbonyl carbons of Q‑pr, Q‑bu and Q‑va were identified at
171.78, 170.48 and 171.01 ppm, respectively. The ions at m/z

381.1, m/z 395.1 and m/z 409.1 in the MS spectra correspond
to sodiated adducts [M+Na]+ for Q‑pr, Q‑bu and Q‑va, respectively, consistent with the C3‑substituted structures. This
further confirmed the successful substitution of aliphatic acyls
at C3.
Q‑pr and Q‑bu exhibited significantly improved water
solubility (Table I). In particular, the water solubility of Q‑pr
was 8.2‑fold higher compared with that of quercetin, while
Q‑bu exhibited a 4.7‑fold higher water solubility. However,
Q‑va did not exhibit improved water solubility, as its water
solubility was only 54% that of quercetin. These results
suggested that the water solubility of quercetin analogues is
affected by the carbon chain length at C3. Propionyl group
has the shortest carbon chain, possessing a total of three
carbons. It was shown to be the most effective in increasing
water solubility. Butyryl group has one more methylene
compared with propionyl group and a total of four carbons.
It was still effective in increasing the water solubility of
quercetin. However, the five‑carbon valeroyl group failed
to render the quercetin analogue more water soluble. This
was probably because 3‑ and 4‑carbon short aliphatic acyl
chains were efficient in disrupting intermolecular packing
of quercetin molecules, thus enabling solvent molecules to
enter the intermolecular gap to solvate quercetin molecules
more easily. A further increase in chain length to 5 carbons
made the hydrophobic effect dominant, making quercetin
substituted with valeroyl group more hydrophobic. Their
n‑octanol/water partition coefficients (Ps) were tested and
three different methods were used to calculate log P (Table I).
The lipophilicity of a compound is reflected by log P. Acyl
chain length increase resulted in stronger lipophilicity. The
results indicate that the log P values of the acylated derivatives were higher than compared with of quercetin, and it
increased with aliphatic acyl chain length with log P of Q‑va
being the highest.
Given that the acylation regioselectively occurred at C3
of quercetin and the bioactive hydroxyl groups remained
unchanged, the biological activities of quercetin were expected
to be maintained. The in vitro assay demonstrated that the
three acylated derivatives were able to inhibit platelet aggregation induced by ADP, AA and PAF in a dose‑dependent
manner (Fig. 3). Q‑pr and Q‑bu were found to be more potent
compared with quercetin.
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Figure 2. Synthetic approach to the synthesis of regioselectively acylated quercetin analogues. Q‑pr, quercetin‑3‑O‑propionate; Q‑bu, quercetin‑3‑O‑butyrate;
Q‑va, quercetin‑3‑O‑valerate; DMF, N,N‑dimethylformamide; DCM, dichloromethane; Pd/C, palladium on carbon.

Figure 3. In vitro antiplatelet aggregation activities of quercetin, Q‑pr, Q‑bu, and Q‑va. Q‑pr, quercetin‑3‑O‑propionate; Q‑bu, quercetin‑3‑O‑butyrate;
Q‑va, quercetin‑3‑O‑valerate; ADP, adenosine diphosphate; AA, arachidonic acid; PAF, platelet‑activating factor.

Figure 4. In vivo antiplatelet aggregation activities of quercetin, Q‑pr, Q‑bu, and Q‑va. *P≤0.01 vs. control. **P≤0.01 vs. quercetin. Q‑pr, quercetin‑3‑O‑propionate;
Q‑bu, quercetin‑3‑O‑butyrate; Q‑va, quercetin‑3‑O‑valerate; ADP, adenosine diphosphate; AA, arachidonic acid; PAF, platelet‑activating factor.

Q‑pr and Q‑bu also displayed higher antiplatelet aggregation activities compared with quercetin in vivo (Fig. 4). In the
ADP group, the AIRs of Q‑pr and Q‑bu were 67.8 and 52.7%,
respectively, which were significantly higher compared with
that of quercetin (43.5%). Although Q‑va successfully inhibited
platelet aggregation to a certain extent with an AIR of 16.0%,
it was significantly less potent compared with quercetin. The
same order of drug activity of the four compounds was also
observed in the AA and PAF groups.
In summary, regioselectively acylated quercetin analogues
were successfully synthesized using a complete synthetic
approach. The water solubility and lipophilicity of the resulting

analogues were affected by the length of the aliphatic chains
for acylation of the hydroxyl group located at C3 of quercetin.
Aliphatic acyl donors containing three and four carbons were
able to improve both the water solubility and the lipophilicity
of the acylated analogues. As compared to quercetin, Q‑pr and
Q‑bu exhibited a higher antiplatelet activity due to the higher
water solubility and enhanced lipophilicity, whereas Q‑va was
less effective than quercetin due to its reduced water solubility,
although its lipophilicity was the highest among the three
analogues. Thus, an optimal acyl chain length is crucial for
the quercetin analogues synthesized following this complete
synthetic approach to be more effective.
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